213 related articles for article (PubMed ID: 24654454)
21. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.
Ushijima K; Yahata H; Yoshikawa H; Konishi I; Yasugi T; Saito T; Nakanishi T; Sasaki H; Saji F; Iwasaka T; Hatae M; Kodama S; Saito T; Terakawa N; Yaegashi N; Hiura M; Sakamoto A; Tsuda H; Fukunaga M; Kamura T
J Clin Oncol; 2007 Jul; 25(19):2798-803. PubMed ID: 17602085
[TBL] [Abstract][Full Text] [Related]
22. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience.
Wang Y; Yu M; Yang JX; Cao DY; Yuan Z; Zhou HM; Zhang Y; Li L; Shen K; Wu H
Int J Clin Oncol; 2019 Jun; 24(6):712-720. PubMed ID: 30746595
[TBL] [Abstract][Full Text] [Related]
23. Trends and characteristics of fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer in Japan: a survey by the Gynecologic Oncology Committee of the Japan Society of Obstetrics and Gynecology.
Ushijima K; Tsuda N; Yamagami W; Mitsuhashi A; Mikami M; Yaegashi N; Enomoto T
J Gynecol Oncol; 2023 May; 34(3):e38. PubMed ID: 36659833
[TBL] [Abstract][Full Text] [Related]
24. Administration of Cabergoline Contributes to Preserving Fertility in Young Hyperprolactinemic Patients With Endometrial Cancer Treated With Medroxyprogesterone Acetate.
Erdenebaatar C; Yamaguchi M; Saito F; Monsur M; Honda R; Tashiro H; Ohba T; Katabuchi H
Int J Gynecol Cancer; 2018 Mar; 28(3):539-544. PubMed ID: 29369118
[TBL] [Abstract][Full Text] [Related]
25. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
[TBL] [Abstract][Full Text] [Related]
26. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option.
Gadducci A; Spirito N; Baroni E; Tana R; Genazzani AR
Gynecol Endocrinol; 2009 Oct; 25(10):683-91. PubMed ID: 19562604
[TBL] [Abstract][Full Text] [Related]
27. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
[TBL] [Abstract][Full Text] [Related]
28. [Clinical outcomes analysis of fertility-preserving therapy for atypical endometrial hyperplasia and early endometrial carcinoma].
He YJ; Wang YQ; Dai YB; Zhou R; Lu Q; Liu GL; Wang JL
Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):291-296. PubMed ID: 35316880
[No Abstract] [Full Text] [Related]
29. [GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy].
Chen JY; Cao DY; Zhou HM; Yu M; Yang JX; Wang JH; Zhang Y; Cheng NH; Peng P
Zhonghua Fu Chan Ke Za Zhi; 2021 Aug; 56(8):561-568. PubMed ID: 34420288
[No Abstract] [Full Text] [Related]
30. Obstetric outcomes after medroxyprogesterone acetate treatment for early stage endometrial cancer or atypical endometrial hyperplasia: a single hospital-based study.
Oishi M; Kasuga Y; Fukuma Y; Hamuro A; Tamai J; Tanaka Y; Hasegawa K; Yoshimura T; Ikenoue S; Ochiai D; Yamagami W; Tanaka M
Int J Clin Oncol; 2023 Apr; 28(4):587-591. PubMed ID: 36662363
[TBL] [Abstract][Full Text] [Related]
31. RNA-seq and ATAC-seq analysis of CD163
Wang L; Lv Q; Wu P; Luo S; Liu S; Chen X; Luo X
Cancer Med; 2023 Mar; 12(5):5964-5978. PubMed ID: 36373483
[TBL] [Abstract][Full Text] [Related]
32. Fertility-Sparing Treatment in Young Women with Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer: A Tertiary Center Experience.
Shikeli S; Gowri V; Rawahi TA
JBRA Assist Reprod; 2020 Oct; 24(4):466-469. PubMed ID: 32569453
[TBL] [Abstract][Full Text] [Related]
33. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia.
Inoue O; Hamatani T; Susumu N; Yamagami W; Ogawa S; Takemoto T; Hirasawa A; Banno K; Kuji N; Tanaka M; Aoki D
Reprod Biol Endocrinol; 2016 Jan; 14():2. PubMed ID: 26769300
[TBL] [Abstract][Full Text] [Related]
34. New therapeutic approaches for the fertility-sparing treatment of endometrial cancer.
Mitsuhashi A; Shozu M
J Obstet Gynaecol Res; 2020 Feb; 46(2):215-222. PubMed ID: 32017321
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer.
Hirata T; Kondo E; Magawa S; Kubo-Kaneda M; Nii M; Yoshida K; Maezawa T; Tabata T; Ikeda T
J Obstet Gynaecol Res; 2022 Dec; 48(12):3219-3225. PubMed ID: 36054237
[TBL] [Abstract][Full Text] [Related]
36. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium.
Minaguchi T; Nakagawa S; Takazawa Y; Nei T; Horie K; Fujiwara T; Osuga Y; Yasugi T; Kugu K; Yano T; Yoshikawa H; Taketani Y
Cancer Lett; 2007 Apr; 248(1):112-22. PubMed ID: 16919866
[TBL] [Abstract][Full Text] [Related]
37. The present status of metformin in fertility-preserving treatment in atypical endometrial hyperplasia and endometrioid endometrial cancer.
Guan J; Chen XJ
Front Endocrinol (Lausanne); 2022; 13():1041535. PubMed ID: 36387903
[TBL] [Abstract][Full Text] [Related]
38. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Zhang H; Yan L; Bai Y; Li C; Guo Q; Wang C; Zhao X; Li M
Gynecol Oncol; 2015 Mar; 136(3):549-53. PubMed ID: 25451692
[TBL] [Abstract][Full Text] [Related]
39. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.
Kaku T; Yoshikawa H; Tsuda H; Sakamoto A; Fukunaga M; Kuwabara Y; Hataeg M; Kodama S; Kuzuya K; Sato S; Nishimura T; Hiura M; Nakano H; Iwasaka T; Miyazaki K; Kamura T
Cancer Lett; 2001 Jun; 167(1):39-48. PubMed ID: 11323097
[TBL] [Abstract][Full Text] [Related]
40. Impact of obesity on the results of fertility-sparing management for atypical hyperplasia and grade 1 endometrial cancer.
Gonthier C; Walker F; Luton D; Yazbeck C; Madelenat P; Koskas M
Gynecol Oncol; 2014 Apr; 133(1):33-7. PubMed ID: 24680589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
